newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting Strong cash